Exclusive sub-licence agreement with SATT Sud-Est

Exclusive sub-licence agreement with SATT Sud-Est

ExAdEx-Innov announces the entry of SATT Sud-Est into its capital and the signing of an exclusive license agreement.

The co-founders of the startup have developed and patented, within academic and hospital research units, the ExAdEx technology, a breakthrough innovation to enable the production of brown fat of therapeutic interest. This biotherapy product, called ObAdEx, is in preclinical development.

After investing in technology transfer and financing a maturation program, SATT Sud-Est entered into an exclusive sub-license agreement with ExAdEx-Innov and acquired a stake in the startup.

As per Vincent Dani, co-founder and President of ExAdEx-Innov, « Having SATT Sud-Est among our shareholders is a major asset for a young start-up like ours and a strong signal of support for our project and our vision« ,

As per Laurent Baly, President of SATT Sud-Est, « We are proud to be associated with the startup ExAdEx-Innov, which has been able to benefit from the transfer of several innovative technologies from Public Research from the Institute of Biology of Valrose. We have been supporting this project for several years and are happy to participate, through it, in the improvement of the pharmaceutical industries (obesity market), reconstructive surgery, cosmetics and nutraceuticals”.

To read the full press release (in French), please click here.


Latest News

KOL on adipose tissue biology.

Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice). 

Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program). 

Co-inventor of 5 patents

Expert in clinical applications of adipose tissue.

Plastic Reconstructive and Aesthetic Surgeon in Nice.

Member of the Medical Council of Alpes Maritimes region.

Expert for the French National Regulatory Agency ANSM for medical devices.

Certified by French Health Autority HAS (2020-2024).

PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.

Expert in cell therapy and immunology. 

Senior Lecturer (Maitre de conférences).

Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).

Director of « Micoralis » research team at Université Côte d’Azur (Nice).

Founder and CEO of the biotech company Biointerférence (2003-2006).

Co-inventor of 5 patents.

Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.

With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov. 

In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille). 

He is co-inventor of the 2 company’s patent families. 

Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue. 

Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.

With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years. 

He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.

Main areas of expertise: Biotech Startup Business Development; Project management